The Future of Precision Cancer Medicines

Pioneering the Discovery of Small Molecule, Tumor-Agnostic Therapies

Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, Tumor-Agnostic Therapies

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.

Black Diamond's MAP Platform

Discover. Reveal. Target.

Mutations

null

Black Diamond Therapeutics mines mutational hotspots for allosteric sites that produce potent oncogenes

Our computational platform integrates multiple forms of genome-level data with a deep understanding of mechanism, structure and dynamics.

Allostery

null

Black Diamond's platform provides insights into how allosteric mutations drive oncogenic activation

Allosterically activated oncogenes are identified by mapping mutation onto regulatory domains and regions involved protein-protein interfaces.

Protein Pharmacology

null

Black Diamond Therapeutics exploits this unique pharmacology to design drugs that are potent and selective for allosteric mutant oncogenes

Allosteric oncogenes are validated through screening in proprietary models of cancer.

Our Vision

Precision Cancer Medicines for Every Genetically Defined Cancer